What's new for 'Trypanosomatids' in PubMed

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.

Sender's message:

Sent on Wednesday, 2010 Feb 17
Search kinetoplastids OR kinetoplastid OR Kinetoplastida OR "trypanosoma brucei" OR leishmania OR brucei OR leishmaniasis OR "African trypanosomiasis"
Click here to view complete results in PubMed. (Results may change over time.)
To unsubscribe from these e-mail updates click here.

PubMed Results

Items 1 -2 of 2

1.	Korean J Ophthalmol. 2010 Feb;24(1):40-3. Epub 2010 Feb 5. Cutaneous leishmaniasis of the lid: a report of nine cases. Yaghoobi R, Maraghi S, Bagherani N, Rafiei A. Department of Dermatology, Research Center of Thalassemia and Hemoglobinopathy, Jondi Shapour University of Medical Sciences, Ahwaz, Iran. Leishmaniasis is a parasitic disease caused by Leishmania species and is classified into three forms; cutaneous, mucocutaneous, and visceral. The eyelid is a rare site involved by leishmaniasis and only makes up 2.5% of cases with cutaneous leishmaniasis (CL). Although CL can affect both upper and lower lids on either their outer or inner aspects, the lateral canthus is most often affected. The most common aspect of lid leishmaniasis is chalazion-like lesions but ulcerous, phagedenic, cancer-like forms, and unilateral chronic granulomatous blepharitis may be observed. When the lid is involved, the disease is usually self-limiting; healing usually takes up to one year, hence early diagnosis and treatment are important. The diagnosis is based on a high index of suspicion regarding the endemicity of the disease in the region. Response to treatment in lid CL cases is quite satisfactory. In this article, we report nine cases of lid leishmaniasis with satisfactory responses to intralesional meglumine antimoniate.
	PMID: 20157413 [PubMed - in process]
	Related articles

2.	Clin Infect Dis. 2010 Feb 15. [Epub ahead of print] Sex and Gender Differences in Travel-Associated Disease. Schlagenhauf P, Chen LH, Wilson ME, Freedman DO, Tcheng D, Schwartz E, Pandey P, Weber R, Nadal D, Berger C, von Sonnenburg F, Keystone J, Leder K. University of Zürich Centre for Travel Medicine, World Health Organisation Collaborating Centre for Travellers' Health, University of Zürich, 2Division of Infectious Diseases, University Hospital of Zürich, and 3Division of Infectious Diseases, University of Zurich Childrens' Hospital, Zürich, Switzerland; 4Mount Auburn Hospital, Cambridge; and 5Harvard Medical School and 6Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts; the 7Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham; 8National Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, Urbana; the 9Chaim Sheba Medical Centre, University of Tel Aviv, Tel Hashomer, Israel; the 10CIWEC Clinic, Kathmandu, Nepal; the 11Department of Tropical and Infectious Diseases, University of Munich, Munich, Germany; the 12Division of Infectious Diseases, University of Toronto, Toronto, Canada; and 13Victorian Infectious Disease Service, Royal Melbourne Hospital, Melbourne, and 14Department of Epidemiology and Preventive Medicine, Monash University, Monash, Victoria, Australia. Background. No systematic studies exist on sex and gender differences across a broad range of travel-associated diseases. Methods. Travel and tropical medicine GeoSentinel clinics worldwide contributed prospective, standardized data on 58,908 patients with travel-associated illness to a central database from 1 March 1997 through 31 October 2007. We evaluated sex and gender differences in health outcomes and in demographic characteristics. Statistical significance for crude analysis of dichotomous variables was determined using chi (2) tests with calculation of odds ratios (ORs) and 95% confidence intervals (CIs). The main outcome measure was proportionate morbidity of specific diagnoses in men and women. The analyses were adjusted for age, travel duration, pretravel encounter, reason for travel, and geographical region visited. Results. We found statistically significant ([Formula: see text]) differences in morbidity by sex. Women are proportionately more likely than men to present with acute diarrhea (OR, 1.13; 95% CI, 1.09-1.38), chronic diarrhea (OR, 1.28; 95% CI, 1.19-1.37), irritable bowel syndrome (OR, 1.39; 95% CI, 1.24-1.57), upper respiratory tract infection (OR, 1.23; 95% CI, 1.14-1.33); urinary tract infection (OR, 4.01; 95% CI, 3.34-4.71), psychological stressors (OR, 1.3; 95% CI, 1.14-1.48), oral and dental conditions, or adverse reactions to medication. Women are proportionately less likely to have febrile illnesses (OR, 0.15; 95% CI, 0.10-0.21); vector-borne diseases, such as malaria (OR, 0.46; 95% CI, 0.41-0.51), leishmaniasis, or rickettsioses (OR, 0.57; 95% CI, 0.43-0.74); sexually transmitted infections (OR, 0.68; 95% CI 0.58-0.81); viral hepatitis (OR, 0.34; 95% CI, 0.21-0.54); or noninfectious problems, including cardiovascular disease, acute mountain sickness, and frostbite. Women are statistically significantly more likely to obtain pretravel advice (OR, 1.28; 95% CI, 1.23-1.32), and ill female travelers are less likely than ill male travelers to be hospitalized (OR, 0.45; 95% CI, 0.42-0.49). Conclusions. Men and women present with different profiles of travel-related morbidity. Preventive travel medicine and future travel medicine research need to address gender-specific intervention strategies and differential susceptibility to disease.
	PMID: 20156059 [PubMed - as supplied by publisher]
	Related articles